Evaluation of TNFRSF11B Gene Polymorphism in Patients with Acute Stroke

Objective: Tumor necrosis factor receptor superfamily, member 11b (TNFRSF11B) has been suggested to be a risk factor for atherosclerosis and cardiovascular diseases because of the observation of osteoporosis and vascular diseases together in human, and the high levels of serum TNFRSF11B in these patients in clinical trials. In this study, we aimed to investigate the association between TNFRSF11B gene 1181G˃C polymorphism and acute stroke as a cerebrovascular disease. Methods: In this study, the DNAs of 107 acute stroke patients and 100 healthy controls have been analyzed by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). Statistical analyses were performed by using chi-square and analysis of variance tests. Results: When we compared the genotype and allele frequencies of patients and controls, any statistically significant differences was not found between them (p=0.476 and p=0.622, respectively). Any association also was not observed when demographical and clinical characteristics of patients was compared with TNFRSF11B gene 1181G˃C polymorphism (p>0.05). Conclusion: As a result, our findings showed that there was no association between TNFRSF11B gene 1181G>C polymorphism and acute stroke. However, further studies can reveal more clearly whether there is a relationship between TNFRSF11B gene polymorphism and acute stroke in Turkish population.

Keywords:

TNFRSF11B, acute stroke polymorphism,

PDF

___

1. Allan H, Ropper RHB. Adams and Victor’s Principles of Neurology, 8 th edn. New York: McGraw-Hill, 2005:660. 2. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statis - tics Subcommittee. Circulation. 2008;117:e25-146. 3. Ayala C, Croft JB, Greenlund KJ, et al. Sex differences in US mortality rates for stroke and stroke subtypes by race/ ethnicity and age,1995-1998. Stroke. 2002;33:1197- 1201. 4. Adams RD, Victor M. Ropper AH. Principles of Neurology, 6 th edn. USA: Mc Graw Hill,1997:777-873. 5. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol. 2002;22:549. 6. Brendan FB, Lianping X. Biology of RANK, RANKL and osteoprotogerin. Arthritis Research &Therapy. 2007;9:1-7. 7. Fata JE, Kong YY, Li J, et al. The Osteoclast differentia - tion factor osteoprotegerin-ligand is essential for mammary gland development. Cell. 2000;103:41-50. 8. Kim NS, Kim HJ, Koo BK, et al. Receptor activator of NF kapa B ligand regulates the proliferation of mammary epi - thelial cells via Id2. Mol Cell Biol. 2006;26:1002-13. 9. Chen G, Sircar K, Aprikian A, et al. Expression of RANK L/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regula - tion. Cancer. 2006;107:289-98. 10. Suda T. Modulation of osteoclast differentiation and func - tion by the new members of the tumor necrosis factor re - ceptor and ligand families. Endocr Rev. 1999;20:345-57. 11. Kong YY. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397:315-323. 12. Blair JM, Zheng Y, Dunstan CR. RANK ligand. Int J Bio - chem Cell Biol. 2007;39:1077-81. 13. Luckish A, Cernes R, Boaz M, et al. Effect of long-term treatment with risedronate on arterial compliance in os - teoporotic patient with cardiovascular risk factors. Bone. 2008;43:279-283. 14. Rumianowska A, Nehring P, Mrozikiewicz-Rakowska B, et al. Osteoprotegerin - a new marker of the atherosclerosis helpful in selecting patients at amputation risk? Leczenie Ran. 2011;8:1-5. 15. Jeffcoate WJ, Rasmussen LM, Hofbauer LC, Game FL. Medial arteria calcification in diabetes and its relationship to neuropathy. Diabetologia 2009;52:2478-88. 16. Biscetti F, Straface G, Giovannini S, et al. Association be - tween TNFRSF11B gene polymorphisms and history of ischemic stroke in Italian diabetic patients. Human Genet 2013;132:49-55. 17. Seremak-Mrozikiewicz A, Barlik M, Drews K, et al. The genetic variants of RANKL/RANK/OPG signal trial in postmenopausal women with osteopenia and osteoporosis. Arch Perinat Med. 2011;17:72-80. 18. Soufi M, SchoppetM, Sattler A, et al. Osteoprotegerin gene polymorphisms in men with coronary artery disease. J Clin Endocrinol Metab. 2004;89:3764-8. 19. Mrozikiewicz A, Barlık M, Drews K, et al. The genetic vari - ants of RANKL\RANK\OPG signal trial in postmenopaus - al women with ostepenia and osteoporosis. Arch Perinat Med. 2011;17:72-8. 20. Straface G, Biscetti F, Pitoco D, et al. Assessment of the genetic effects of polymorphism in the osteoprotegerin gene,TNFRSF11B, on serum osteoprotegerin levels and carotid plaque vulnerability. Stroke. 2011;24:3022-8.